Payzone - Actually thinking back to the AGM, DM did say that Merck was getting excited about the results in our trial because up until now(Oct 2022) they were not having much success with Keytruda in prostate cancer. By haulting that trial it may be a very good sign for ZEN-3694. It will be interesting to see if a PIII trial is being planned for the combination of Keytruda, Xtandi and ZEN-3694.

tada